This is a type of tuberculosis where the bacteria that causes it are resistant to two or more medicines used to treat it. It's harder to treat and often needs stronger, more toxic medicines. This is sometimes called MDR-TB.
Every report comes from a Lived member, sent anonymously.
Have you tried Zyvox (Linezolid) for Drug-Resistant Tuberculosis?
Drug-resistant tuberculosis (TB) is TB caused by bacteria that no longer respond to one or more of the standard medicines used to cure it. The most important form is multidrug-resistant TB (MDR-TB), in which the bacteria resist at least isoniazid and rifampin, the two most powerful first-line TB drugs. Because those two drugs carry the usual treatment, MDR-TB needs a different combination of medicines, closer monitoring and specialist care. In most other ways it is the same illness as ordinary TB. It usually affects the lungs, causing a cough that lasts for weeks, sometimes with blood, along with fever, night sweats, tiredness and weight loss. It can also affect other parts of the body. Like other TB in the lungs, it spreads through the air when someone with active disease coughs or talks. Some strains resist additional drugs as well, including the fluoroquinolone antibiotics; these forms, called pre-extensively and extensively drug-resistant TB (pre-XDR and XDR-TB), leave fewer treatment options. Drug-resistant TB is treatable and often curable.
Resistance develops in two ways. It can arise inside one person when TB medicines are not used as intended: the wrong drugs or doses are prescribed, the medicines are of poor quality, or treatment is stopped early or taken irregularly. The bacteria that survive are the ones that resist the drugs, and they then multiply. Resistance can also be caught directly: a person who breathes in bacteria from someone with drug-resistant TB develops a resistant infection from the start, even if they have never taken TB medicine. The risk is higher for people who were treated for TB before, especially if treatment was interrupted, and for people who were born in or spent time in countries where drug-resistant TB is more common. Close contact with someone who has infectious drug-resistant TB, particularly in a household, raises the risk, and young children and people with HIV are more likely to become ill after infection. Factors that make TB disease more likely in general, such as diabetes, HIV, undernutrition, smoking, heavy alcohol use and medicines that weaken the immune system, apply here too.
Diagnosis starts the same way as for any TB: a chest X-ray and samples of sputum (mucus coughed up from the lungs), or tissue or fluid from another affected site, tested for TB bacteria. A skin test or blood test can show TB infection but cannot tell whether the infection is active or drug-resistant. What sets drug-resistant TB apart is testing the bacteria themselves against the medicines. Rapid molecular tests look for genetic changes linked to resistance, especially rifampin resistance, and can give an answer within days. Guidelines recommend a rapid rifampin resistance test for everyone with TB, and especially for people at higher risk. Growing the bacteria in culture and testing them against each drug takes weeks but confirms which medicines will work, and some laboratories use genetic sequencing to check resistance to many drugs at once. These results shape the regimen, so testing for resistance to second-line drugs, such as the fluoroquinolones, also matters. An HIV test is part of the initial assessment.
Treatment combines several antibiotics the bacteria are still sensitive to, chosen from resistance testing and usually guided by a TB specialist and the local health department. Using several drugs together kills the bacteria and stops new resistance from developing. Treatment has changed considerably. It once meant 18 to 24 months of many pills, often with daily injections and frequent side effects. Today, most adults and adolescents 14 and older with drug-resistant TB in the lungs can take an all-oral 6-month regimen called BPaLM: bedaquiline (Sirturo), a newer TB antibiotic; pretomanid, another newer TB drug; linezolid, an antibiotic also used for other serious infections; and moxifloxacin, a fluoroquinolone antibiotic. When the bacteria also resist fluoroquinolones, the same regimen without moxifloxacin (BPaL) is used. In a trial, 89% of people on BPaLM were treated successfully compared with 52% on older longer regimens, with fewer serious side effects, although the evidence comes from small studies. Some people need longer, individually designed regimens, including children under 14, people who are pregnant or breastfeeding, those with severe TB outside the lungs and those with resistance to the newer drugs. The main trade-off is side effects. Linezolid can damage nerves, causing numbness or tingling in the hands and feet, and the optic nerve, affecting vision, and it can lower blood counts. These problems usually improve when the dose is lowered or the drug is paused, which is why vision checks and blood tests are done every month. The regimen can also affect the liver and heart rhythm, so liver blood tests and ECGs (heart tracings) are part of routine monitoring. Nausea, tiredness and joint aches are common and often manageable. Close contacts of someone with infectious drug-resistant TB are usually tested. Those found to be infected may be offered preventive treatment, often 6 to 12 months of a fluoroquinolone, because observational studies suggest it lowers the chance of developing the disease.
Treatment is a significant commitment, even at 6 months. Many people take their medicines with a health worker watching, in person or by video, a method called directly observed therapy (DOT) that helps people stay on track and is linked to better results. Stopping early or dropping one of the drugs can make treatment fail and allow further resistance, so problems with side effects or with getting to appointments are best raised with the care team rather than handled by skipping doses. People usually start to feel better within weeks, and effective treatment makes them noninfectious fairly quickly, so most can be treated at home. Until the care team confirms otherwise, they may need to stay home from work or school and limit visitors, particularly young children and people with weakened immune systems. Sputum tests are repeated regularly to confirm the bacteria are clearing, alongside the monthly blood, vision and heart checks. The experience can be isolating and expensive, and stigma is common. Health department case managers often help with practical needs such as transport, food and income support. After treatment ends, follow-up visits with sputum tests and imaging continue for at least 1 to 2 years to make sure TB has not returned.
Get tested for TB if you have a cough lasting more than 3 weeks, coughing up blood, unexplained weight loss, fever or night sweats, especially if you have had TB before or have spent time with someone who has drug-resistant TB. Anyone told they are a close contact of a person with drug-resistant TB should follow up with the health department, even without symptoms. During treatment, contact your care team promptly about changes in vision or color vision, new numbness, tingling or pain in the hands or feet, yellowing of the skin or eyes, dark urine, a fast or irregular heartbeat or fainting, or vomiting that stops you from taking your medicines. Tell the team as well if symptoms return or worsen after first improving.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Drug-Resistant Tuberculosis is like, what's helped you, or ask the community a question.